In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula ...

Hana Securities stated that the selection of new stocks to be added to the MSCI index in February next year is highly likely to be determined by ...

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

Eli Lilly and Company has announced two significant strategic developments that could reshape its long-term growth trajectory ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major ...

Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

ABL Bio has unveiled a strategy to expand its bispecific antibody platform technology, which has been focused on brain ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Eli Lilly invests 22 billion won in ABL Bio to fund Grabody research Lilly to receive 175,079 ABL Bio shares as part of strategic R&D partnership ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...